SCHEMBL1004237 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	GRM5	P41594	1/20	0.43

▸	HDAC1	Q13547	1/20	0.40

▸	HDAC8	Q9BY41	1/20	0.40

▸	HDAC6	Q9UBN7	1/20	0.40

▸	ALOX15	P16050	2/20	0.39

▸	NPC1	O15118	1/20	0.39

▸	RAB9A	P51151	1/20	0.39

▸	KDM5B	Q9UGL1	1/20	0.38

▸	ENPP3	O14638	2/20	0.37

▸	ENPP1	P22413	2/20	0.37

▸	KDM4E	B2RXH2	2/20	0.36

▸	ALDH1A1	P00352	2/20	0.36

▸	HPGD	P15428	2/20	0.36

▸	CYP1A2	P05177	1/20	0.36

▸	CYP3A4	P08684	1/20	0.36

▸	CYP2C19	P33261	1/20	0.36

▸	NPSR1	Q6W5P4	1/20	0.36

▸	S1PR1	P21453	1/20	0.36

▸	S1PR3	Q99500	1/20	0.36

▸	PDE4B	Q07343	2/20	0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL1002392	0.84	GRM5 (0.43)	GRM5HDAC1HDAC8HDAC6ALOX15
SCHEMBL1002380	0.81	GRM5 (0.49)	GRM5HDAC1HDAC8HDAC6ALOX15
SCHEMBL1002924	0.79	LMNA (0.39)	GRM5HDAC1HDAC8HDAC6KDM5B
SCHEMBL15802660	0.75	KDM4E (0.42)	HDAC1HDAC8HDAC6RAB9AKDM5B
SCHEMBL1003962	0.73	NPC1 (0.47)	HDAC1HDAC8HDAC6ALOX15NPC1
SCHEMBL1002103	0.73	ALOX15 (0.44)	ALOX15NPC1RAB9AKDM4EALDH1A1
SCHEMBL1001407	0.73	HDAC1 (0.42)	HDAC1HDAC8HDAC6KDM5BENPP3
SCHEMBL7945448	0.73	MMP13 (0.42)	HDAC1HDAC8HDAC6KDM5BENPP3
SCHEMBL1004600	0.72	KDM5B (0.41)	HDAC1HDAC8HDAC6KDM5BENPP3
SCHEMBL1002137	0.72	KDM5B (0.41)	HDAC1HDAC8HDAC6RAB9AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9045467-B2	Oxazole derivatives useful as inhibitors of FAAH	MERCK SHARP & DOHME CORP. (US)	2015-06-02	—	—	US	disclosed
US-20140171437-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME CORP. (US)	2014-06-19	—	—	US	disclosed
EP-2321288-B1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME (US)	2014-03-19	—	—	EP	disclosed
US-8673941-B2	Oxazole derivatives useful as inhibitors of FAAH	MERCK SHARP & DOHME CORP. (US)	2014-03-18	—	—	US	disclosed
US-8673941-B2	Oxazole derivatives useful as inhibitors of FAAH	MERCK SHARP & DOHME CORP. (US)	2014-03-18	—	—	US	disclosed
US-8673941-B2	Oxazole derivatives useful as inhibitors of FAAH	MERCK SHARP & DOHME CORP. (US)	2014-03-18	—	—	US	disclosed
US-20130030000-A1	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS	MERCK SHARP & DOHME CORP.	2013-01-31	—	—	US	disclosed
US-20130030000-A1	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS	MERCK SHARP & DOHME CORP.	2013-01-31	—	—	US	disclosed
US-20130030000-A1	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS	MERCK SHARP & DOHME CORP.	2013-01-31	—	—	US	disclosed
CN-102858338-A	Pharmaceutical compositions for the treatment of pain and other indications	MERCK SHARP & DOHME	2013-01-02	—	—	CN	disclosed
US-20110144119-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME LLC	2011-06-16	—	—	US	disclosed
US-20110144119-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME LLC	2011-06-16	—	—	US	disclosed
US-20110144119-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME LLC	2011-06-16	—	—	US	disclosed
US-20110021531-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME CORP.	2011-01-27	—	—	US	disclosed
US-20110021531-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME CORP.	2011-01-27	—	—	US	disclosed
US-20110021531-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK SHARP & DOHME CORP.	2011-01-27	—	—	US	disclosed
WO-2010017079-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	MERCK & CO., INC. (US)	2010-02-11	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110144119-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	FAAH, FAAH2, ALOX5	GRM5 179/4885HDAC1 704/4885HDAC8 796/4885
US-20140171437-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	FAAH, FAAH2, ALOX5	GRM5 179/4885HDAC1 704/4885HDAC8 796/4885
US-20110021531-A1	OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH	FAAH, FAAH2, ALOX5	GRM5 170/4885HDAC1 715/4885HDAC8 714/4885
US-20130030000-A1	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS	FAAH, FAAH2, CNR2	GRM5 360/4885HDAC1 1337/4885HDAC8 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.